Piramal Healthcare, country’s largest drug maker is likely to invest Rs 200 crore on various research and development activities this fiscal, including clinical trials for its two cancer molecules. It is currently conducting Phase I clinical trials for its tumour suppressor treatment molecule 'P1446A- 05' and blood cell cancer treatment molecule 'P2745'.
The company is also working on an investigational new drug (IND) application for conducting Phase I clinical studies of a molecule code named 'P7170'. The trial results of the molecules are being presented at the annual general meeting of the American Association for Cancer Research (AACR) being held at Chicago.
Piramal Healthcare, formerly known as Nicholas Piramal, is one of the largest pharmaceutical companies in India. Being part of Piramal Group, its healthcare division contributes 50% to group’s revenue. Besides healthcare, the Piramal Group has business interests in areas of glass manufacturing, retail and real estate.
